Global Rare Disease Drug Market Insights, Forecast to 2025

Table of Contents

1 Study Coverage

• 1.1 Rare Disease Drug Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Rare Disease Drug Market Size Growth Rate by Product
  • 1.4.2 >1‰
  • 1.4.3 0.65‰～1‰
  • 1.4.4 <0.1‰
• 1.5 Market by End User
  • 1.5.1 Global Rare Disease Drug Market Size Growth Rate by End User
  • 1.5.2 Hospital Pharmacies
  • 1.5.3 Speciality Pharmacies
  • 1.5.4 Retail pharmacies
  • 1.5.5 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Rare Disease Drug Market Size
  • 2.1.1 Global Rare Disease Drug Revenue 2014-2025
  • 2.1.2 Global Rare Disease Drug Sales 2014-2025
• 2.2 Rare Disease Drug Growth Rate by Regions
  • 2.2.1 Global Rare Disease Drug Sales by Regions
  • 2.2.2 Global Rare Disease Drug Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Rare Disease Drug Sales by Manufacturers
  • 3.1.1 Rare Disease Drug Sales by Manufacturers
  • 3.1.2 Rare Disease Drug Sales Market Share by Manufacturers
  • 3.1.3 Global Rare Disease Drug Market Concentration Ratio (CR5 and HHI)
• 3.2 Rare Disease Drug Revenue by Manufacturers
  • 3.2.1 Rare Disease Drug Revenue by Manufacturers (2014-2019)
  • 3.2.2 Rare Disease Drug Revenue Share by Manufacturers (2014-2019)
• 3.3 Rare Disease Drug Price by Manufacturers
• 3.4 Rare Disease Drug Manufacturing Base Distribution, Product Types
  • 3.4.1 Rare Disease Drug Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Rare Disease Drug Product Type
  • 3.4.3 Date of International Manufacturers Enter into Rare Disease Drug Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Rare Disease Drug Sales by Product
• 4.2 Global Rare Disease Drug Revenue by Product
• 4.3 Rare Disease Drug Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Rare Disease Drug Breakdown Data by End User

6 North America

• 6.1 North America Rare Disease Drug by Countries
  • 6.1.1 North America Rare Disease Drug Sales by Countries
  • 6.1.2 North America Rare Disease Drug Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Rare Disease Drug by Product
• 6.3 North America Rare Disease Drug by End User

7 Europe

• 7.1 Europe Rare Disease Drug by Countries
  • 7.1.1 Europe Rare Disease Drug Sales by Countries
  • 7.1.2 Europe Rare Disease Drug Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Rare Disease Drug by Product
• 7.3 Europe Rare Disease Drug by End User

8 Asia Pacific

• 8.1 Asia Pacific Rare Disease Drug by Countries
  • 8.1.1 Asia Pacific Rare Disease Drug Sales by Countries
  • 8.1.2 Asia Pacific Rare Disease Drug Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Rare Disease Drug by Product
• 8.3 Asia Pacific Rare Disease Drug by End User

9 Central & South America

• 9.1 Central & South America Rare Disease Drug by Countries
  • 9.1.1 Central & South America Rare Disease Drug Sales by Countries
  • 9.1.2 Central & South America Rare Disease Drug Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Rare Disease Drug by Product
• 9.3 Central & South America Rare Disease Drug by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Rare Disease Drug by Countries
  • 10.1.1 Middle East and Africa Rare Disease Drug Sales by Countries
  • 10.1.2 Middle East and Africa Rare Disease Drug Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Rare Disease Drug by Product
• 10.3 Middle East and Africa Rare Disease Drug by End User

11 Company Profiles

• 11.1 Novartis AG
  • 11.1.1 Novartis AG Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Novartis AG Rare Disease Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Novartis AG Rare Disease Drug Products Offered
  • 11.1.5 Novartis AG Recent Development
• 11.2 Bristol-Myers Squibb Company
  • 11.2.1 Bristol-Myers Squibb Company Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Bristol-Myers Squibb Company Rare Disease Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Bristol-Myers Squibb Company Rare Disease Drug Products Offered
  • 11.2.5 Bristol-Myers Squibb Company Recent Development
• 11.3 Celgene Corporation
  • 11.3.1 Celgene Corporation Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Celgene Corporation Rare Disease Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Celgene Corporation Rare Disease Drug Products Offered
  • 11.3.5 Celgene Corporation Recent Development
• 11.4 F. Hoffmann-La Roche Ltd.
  • 11.4.1 F. Hoffmann-La Roche Ltd. Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 F. Hoffmann-La Roche Ltd. Rare Disease Drug Products Offered
  • 11.4.5 F. Hoffmann-La Roche Ltd. Recent Development
• 11.5 Pfizer, Inc.
  • 11.5.1 Pfizer, Inc. Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Pfizer, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Pfizer, Inc. Rare Disease Drug Products Offered
  • 11.5.5 Pfizer, Inc. Recent Development
• 11.6 Sanofi S.A.
  • 11.6.1 Sanofi S.A. Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Sanofi S.A. Rare Disease Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Sanofi S.A. Rare Disease Drug Products Offered
  • 11.6.5 Sanofi S.A. Recent Development
• 11.7 Alexion Pharmaceuticals, Inc.
  • 11.7.1 Alexion Pharmaceuticals, Inc. Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Alexion Pharmaceuticals, Inc. Rare Disease Drug Products Offered
  • 11.7.5 Alexion Pharmaceuticals, Inc. Recent Development
• 11.8 Eli Lilly and Company
  • 11.8.1 Eli Lilly and Company Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Eli Lilly and Company Rare Disease Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Eli Lilly and Company Rare Disease Drug Products Offered
  • 11.8.5 Eli Lilly and Company Recent Development
• 11.9 Novo Nordisk A/S
  • 11.9.1 Novo Nordisk A/S Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Novo Nordisk A/S Rare Disease Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Novo Nordisk A/S Rare Disease Drug Products Offered
  • 11.9.5 Novo Nordisk A/S Recent Development
• 11.10 AstraZeneca
  • 11.10.1 AstraZeneca Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 AstraZeneca Rare Disease Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 AstraZeneca Rare Disease Drug Products Offered
  • 11.10.5 AstraZeneca Recent Development
• 11.11 Eisai Co., Ltd.
• 11.12 Daiichi Sankyo Company Limited
• 11.13 Bayer AG
• 11.14 GlaxoSmithKline
• 11.15 Merck & Co., Inc.
• 11.16 Johnson & Johnson
• 11.17 Biogen, Inc.
• 11.18 Shire
• 11.19 Amgen, Inc.
• 11.20 Deciphera
• 11.21 Atara Biotherapeutics
• 11.22 ProQR

12 Future Forecast

• 12.1 Rare Disease Drug Market Forecast by Regions
  • 12.1.1 Global Rare Disease Drug Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Rare Disease Drug Revenue Forecast by Regions 2019-2025
• 12.2 Rare Disease Drug Market Forecast by Product
  • 12.2.1 Global Rare Disease Drug Sales Forecast by Product 2019-2025
  • 12.2.2 Global Rare Disease Drug Revenue Forecast by Product 2019-2025
• 12.3 Rare Disease Drug Market Forecast by End User
• 12.4 North America Rare Disease Drug Forecast
• 12.5 Europe Rare Disease Drug Forecast
• 12.6 Asia Pacific Rare Disease Drug Forecast
• 12.7 Central & South America Rare Disease Drug Forecast
• 12.8 Middle East and Africa Rare Disease Drug Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Rare Disease Drug Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details